This is a binary regulatory catalyst for a single-asset clinical-stage biotech. Monitor for the resubmission acceptance and any FDA review timeline updates. The stock is likely to re-rate on the probability of approval; watch for potential PDUFA date assignment and any advisory committee meeting announcements.
Price Chart
Executive Summary
Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma, following collaborative discussions with the FDA. The FDA has indicated it will treat the resubmission as an urgent matter and prioritize its review, citing significant unmet need. This is a material regulatory catalyst for a clinical-stage biotech with no approved products, as RP1 is the company's lead asset.
Key Facts
- Replimune will resubmit the RP1 BLA for advanced melanoma in combination with nivolumab in the coming days.
- FDA will treat the BLA resubmission as an urgent matter and prioritize its review.
- Approximately 8,500 Americans with advanced melanoma die each year; standard checkpoint inhibitor therapy fails about half of patients.
- The BLA is supported by data from the IGNYTE clinical trial in patients with confirmed progression on anti-PD-1 therapy.
- Company is a clinical-stage biotechnology firm with no approved products; RP1 is the lead candidate.
Financial Impact
No financial figures provided in the filing. The event is a regulatory catalyst for a pre-revenue biotech; approval would open a large addressable market in advanced melanoma.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) after review, despite the collaborative tone.
- Clinical data from IGNYTE may not be sufficient for approval; no efficacy or safety results were disclosed in this filing.
- Company has no approved products and is pre-revenue; any regulatory setback would be value-destructive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068002 |
| Document: tm2615980d1_ex99-1.htm | 0001104659-26-068002 |
| Document: 0001104659-26-068002-index-headers.html | 0001104659-26-068002 |
| Document: 0001104659-26-068002-index.html | 0001104659-26-068002 |
| Document: 0001104659-26-068002.txt | 0001104659-26-068002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access